Core Viewpoint - Jade Biosciences, Inc. has announced a PIPE financing agreement expected to generate approximately $135 million in gross proceeds to fund its research and development efforts for autoimmune disease therapies [1][4]. Financing Details - The PIPE financing involves the sale of 13,368,164 shares of common stock at a price of $9.14 per share and pre-funded warrants for 1,402,092 shares at a price of $9.1399 per warrant [3]. - The transaction is anticipated to close on or about October 8, 2025, pending customary closing conditions [3]. Investor Participation - The financing attracted both new and existing investors, including notable firms such as Janus Henderson Investors, Fairmount, and RA Capital Management [2]. Use of Proceeds - The net proceeds from the PIPE financing will be utilized for research and development, general corporate expenses, and working capital needs, with expectations to fund operations into the first half of 2028 [4]. Company Overview - Jade Biosciences is focused on developing therapies for autoimmune diseases, with its lead candidate, JADE101, currently in a Phase 1 clinical trial for immunoglobulin A nephropathy (IgAN) [7]. - The company also has a second candidate, JADE201, and an undisclosed antibody discovery program in preclinical development [7].

Core Points - ProMIS Neurosciences, Inc. has announced a private investment in public equity (PIPE) financing, raising approximately $2.4 million through the issuance of warrants, with total gross proceeds expected to reach $9.2 million when including additional funds from existing warrant exercises [1][3] - The warrants have an exercise price of $1.25 per share, are immediately exercisable, and will expire five years from the date of issuance [2] - Proceeds from the PIPE financing will be utilized to advance the clinical development of PMN310, the company's lead therapeutic candidate, as well as for working capital and general corporate expenses [4] Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapeutic antibodies targeting toxic misfolded proteins associated with neurodegenerative diseases, including Alzheimer's disease, ALS, and Parkinson's disease [7] - The company employs a proprietary target discovery engine, EpiSelect™, to identify Disease Specific Epitopes (DSEs) on misfolded proteins, which are implicated in various neurodegenerative conditions [7]

Core Viewpoint - SRM Entertainment, Inc. has entered into a PIPE financing agreement expected to generate approximately $5 million in gross proceeds for the company [1] Group 1: Financing Details - The company is selling 5,000 shares of Series A Convertible Preferred Stock, convertible into 10 million shares of common stock at a conversion price of $0.50 per share [3] - Each share of Series A Convertible Preferred Stock and one warrant is priced at $1,000, with warrants exercisable at $0.65 per share for two years [3] - Dominari Securities LLC acted as the sole placement agent for the PIPE financing [4] Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including working capital [2] Group 3: Company Overview - SRM Entertainment designs and manufactures licensed media-themed merchandise, including toys and souvenirs for major theme parks and entertainment venues [7] - The company’s products are based on popular multi-billion-dollar entertainment franchises and are distributed globally at various attractions [7]